Browse by author
Lookup NU author(s): Professor Matthew CollinORCiD
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
© 2023 British Society for Haematology and John Wiley & Sons Ltd. BRAF and MEK inhibitors have revolutionised the treatment of patients with high-risk histiocytic neoplasms but does a complete response mean that treatment can be withdrawn?. Commentary on: Reiner et al. Outcomes after interruption of targeted therapy in patients with histiocytic neoplasms. Br J Haematol 2023 (Online ahead of print). doi: 10.1111/bjh.18964.
Author(s): Collin M
Publication type: Note
Publication status: Published
Journal: British Journal of Haematology
Year: 2023
Volume: 203
Issue: 3
Pages: 347-348
Print publication date: 01/11/2023
Online publication date: 17/08/2023
Acceptance date: 22/07/2023
ISSN (print): 0007-1048
ISSN (electronic): 1365-2141
Publisher: John Wiley and Sons Inc.
URL: https://doi.org/10.1111/bjh.19014
DOI: 10.1111/bjh.19014
PubMed id: 37592718